PDF Page 1
(XX y.o. X) (Adm: XXXXXXXX)
Guarantor Information
Name:
SSN:
Address:
City:
XXXXXXXXXXXX: IL
Zip:
Phone:
Employer:
Address:
City:
State:
Zip:
Phone:
Guar DOB:
Emergency Contact Information
Name:
Relationship: CH
Address:
City:
XXXXXXXXXXXX: IL
Zip:
Phone:
Business
phone:
Principal Problem Audit Trail
Problem
Noted By
Date/Time
XXXXXX XXXX in XXXXXX
XXXXXXXX 1231
Medical Problems
Hospital Problem List
Date Reviewed: XXXXXXXXXX
ICD-10-
CM
Priority
Class
Noted
POA
* (Principal) XXXXXX XXXX in XXXXXX
R19.00
XXXXXXXXX Unknown
Preop testing
Z01.818
XXXXXXXXXX Unknown
Acute XXXXXXXXXX as cause of
D62
XXXXXXXXXX Yes
postoperative XXXXXX
Essential XXXXXXXXXXXXXX (CMS-HCC)
D47.3
XXXXXXXXXX Yes
Non-Hospital Problem List
Date Reviewed: XXXXXXXXXX
ICD-10-
CM
Priority
Class
Noted
XXXXXXXXXX
L03.90
XXXXXXXXX
Acute XXXXXXXXXXXXXXXXXXXX (XXX) of XXXXXXXXXXXX of 182.412
XXXXXXXXX
left lower XXXXXXXXX (CMS-HCC)
Acute XXXXXXXXXXXXXXXXXX without acute cor
126.99
XXXXXXXXX
XXXXXXXXX (CMS-HCC)
Presence of IVC filter RETRIEVABLE
Z95.828
XXXXXXXXX
Overview Signed XXXXXXXXX 8:36 AM by
inted at XXXXXXXXXX 1:59 PM

PDF Page 2
ICD-10-
CM
Priority
Class
Noted
RetrievableXXXXXXXXXXXXXXXXXd atXXXH onXXXXXXXXXX3 by Dr.
AcuteXXE &XXXT withXXXXXXcXXXXs. NeedsXXXXs resection
Care Plan Problems
Clinical Goals
PCP
Patient Demographics
Name
Patient ID
Gender Identity
Birth DateXXXXXXe
(80 yrs)
Address
Phone
Email
Reg Status
PCP
Date Last Verified
Next Review Date
Verified
Demographics
Address:
Home Phone:
Work Phone:
Mobile Phone:
SSN:
Insurance:
Marital Status:
Religion:
MEDICAID
Widowed
REPLACEMENT
Documents Filed to Patient
After
Lab
Power of Living
Clinical
Study
Consent
ABN
Visit
Result
Code
MyNM
Attorney Will
Unknown
Attachment
Form
WaiverXXXXXXXXXXXXn
Status
Status
Not on
Not on
Not on
Not on File
Filed
Not on
Filed
Not on
FULL
Pending
File
File
File
File
File
[Updated
onXXXXXXXX3
1245]
Admission Information
Current Information
Attending Provider
Admitting Provider
Admission Type
Admission Status
Elective
Confirmed Admission

PDF Page 3
Inpatient Admission
Admission Date/Time
Date/Time
Discharge Date
Hospital ServicXXXXXXXX2XXXX2XXXXXXXX2XXXXXXXXXXXXXXXXXXXXXal Area
Unit
Room/Bed
Auth/Cert Status
CENTRAL DUPAGE
CDH GENERAL SURGERY 249/A
Incomplete
HOSPITAL IP
XXXXXXXXXXXXXXXXXXXXal Account
Name
Acct ID
Class
Status
Primary CoveragXXXXXXXXXXXXXXXXXXXXXXXXXNT XXXXXXXXXXXXXXXXXXXXAN OF
IL
Guarantor Account (for Hospital Account #
Relation
Name
to Pt
Service Area
Active?
Acct Type
SelXXXMH
Yes
Personal/Family
Address
Phone
Coverage Information (for Hospital AccountXXXXXXXX47)
F/O Payor/Plan
Precert XXXXXXXXXXXXXXXXXXXXNXXXXXXXXXXXXXXXTH PLAN OF IL
Subscriber
Subscriber #
Address
Phone
H&P Notes
MD (PhysicianXXXXXXXXXX23 17:08 Hospitalist
CDIP Hospitalist Admission H&P
Patient name:
Room:
Date of admissionXXXXXXXXXX23
Primary care physician:
CODE STATUS: full
Chief complaintXXX/XXXXXap, R oophrecotmy, LOAXXXXXXXXXXXmy
HPI:
with a history of essentiaXXXXXXXXXXXXXXisXXXVTXXPXXX/XXXVC

PDF Page 4
filter, B12 deficienXXXXXXmiXXXXXXvXXXXass, admittXXXXXXXXXX0XXXsXXXXXlap, R oophrecotmXXXLOXXXXXXXXXXXomy. Pt's daughter at bedside interpreting. Pt c/o 5/XXXXain "all over". Denies
specifXXXXXXXXXnXXXXain. DeniXXXXXXsea.
ROS:
10 point ros (-) except as stated aboXXXXXXXXXXXXXXnal: deniXXXXXXXXXXXosXXXXXXeXXXXyes: deniXXXXXXXXXXXXXXgeXXXeXXXXaXXXXXXXXXXXXXXXXXXXXXoat: deniXXXXXXXXcXXXXXXXXXXXXXXXtXXXXosXXXeXXXXaiXXXXXXXXtuXXXXXXXXXXXgXXXCV. deniXXXXXeXXXXaiXXXDOXXXPNXXXXXXXXXneXXXXXXXXXXXXoXXXXulm: deniXXXXXugXXXXXXtuXXXXXXXXinXXXXXXXXXXsiXXXSXX
GI: deniXXXXXXXXXnXXXXaiXXXXXXXXXgiXXXXXXXXXXXXXXXinXXXXXXXXXXXXXXXXXXXXXioXXXXXXXXXXXsiXXXXXBPXXXXXXeXX
GU: deniXXXXXXXriXXXXXXXXXXXXnXX
MS: deniXXXXXiXXXXaiXXXXXXXXXesXXXXXXXXiXXXXkin: deniXXXXXXXXtiXXXXXXheXXXXXXXonXXXXXXXlXXXXXuro: deniXXXXXXXXesXXXXXXXXinXXXXXXxiXXXXXXXXXXXXXXXeXXXXXych: deniXXXXXXXXXXXXXXXXXXceXXXXXXXXXXion XXXXXXXXXXXXXXXXXXues
Past Medical History:
Diagnosis
DaXXXXXXmia
EssentiXXXXXXXXXXXXion, beniXX
PXXXXXXXXXaXXXXXXXXXXXXXXXism) (CMS-HCXXXXXXXXXXXXXXsXXXXXXXXXXXXXXXXXXXXXXXncy
Past Surgical HistorXXXXXXXXXure
Laterality
DaXXXXXXXXXXXXXXXEXXXXXXXXXX0XXXXXXXXXXXXXXXXXXXXXXomy, rigXXXXXXXXXXXXomXXXXXXvic aXXXXXXXXXXXXXXXXXXXXXXXXXXomXXXXXXXXXXXXXXXXXXXXXXXXomy, right ureterolysis with DXXXXXter @ CXXXXXXXXXXXXOXXXXXXXXXXXXXXPXXXXXXXXXXXRXXXXXXXXXX023
XXXXXXPXXXXXXXXXXXRXXXXXXXXX023 CDH INTERVENTIONAL LABS
XXXXXXXXXXXXXXXXXXXXEXXXXXXXXXX023
XXXXXXXXXXXXXXXXXXXXEXXXXXXXXX023 CDH INTERVENTIONAL LABS
Family History
Problem
Relation
Age of OnsXXXXXXaXXXXXXcer
Neg XXXXXXXiXXXXXXcer
Neg XXXXXXXiXXXXXXcer
Neg Hx
Social History
Socioeconomic History

PDF Page 5
Marital status:
WidoXXXXXXXacco Use
Smoking status:
Never
SmokelXXXXXXXacco:
Never
Vaping Use
Vaping Use:
Never used
Substance and Sexual Activity
Alcohol use:
No
Drug use:
No
Sexual activity:
Defer
Social History Narrative
NumberXXXXXXXXXXXcies - 8
NumberXXXXXXXXXXXXages - 4
Age at menarchXX- 12
Age at first live birtXX-XXXXXXeast feed children - XXXXXXXXXXXXtomy - XXXXXXXXXXXXtomy - Yes (both)
Menstruating regularly - No
Currently takXXXXXXXXXXXXXXXXXXXills - No
Ever taXXXXXXXXXXXXXXXXXXXills -XXXXXXXXXause - Yes
Currently takXXXXXXXXXXXXXXXXXXXXXXXXXXXrapy - No
Ever taXXXXXXXXXXXXXXXXXXXXXXXXXXXrapy - No
PrXXXXXXXXXXXXXXXsies - No
Social Determinants of Health
Food Insecurity: Low RiXXXXXXXXX2023)
Food Insecurity
Have there been times that your food ran out and you didn't have money to get
more? : No
Have there been any times recently that you worried whether your food would run out
before you got money to buy more?: No
Transportation Needs: Low RiXXXXXXXXX2023)
Transportation Needs
Do you have trouble getting transportation to medical appointments?: No
Housing Stability: Low RiXXXXXXXXX2023)
Housing Stability
Are you concerned about having a safe and reliable place to live?: No
No Known Allergies
HXXXXXXXXXXXioXXXXXXXXXXXions Prior to AdmissXXXXXXXXXXtion
Sig
Dispense Refill Last DXXXXXXXXXXXXXphen 325 mg
Take 2 tablets by
30 tablet
0
Unknown
tablet
mouth every 4
PDF Page 6
(four) hours as
needed.

PDF PaXXXXXXXXxaXXXXXXXIXXXS DVT-PE
Take 2 tablets (10
74 tablXXXXXXXXXX/2023
TREAT 30D START) 5 mg
mg total) by mouth
(74 tabs) tablets, dose pack
2 (two) times a
day for 7 days,
then take 1 tablet
(5 mg totalXXXXXmouth 2 (two)
times aXXXXXXXXXXXXXXXXXXXXXXXXXse-gl
1 drop if neeXXXXXXXXXX/XXXXXycXXXXXXXXXXXXXXPTIVE)
0.5-0.9 % DXXXXXXXXXXXXXXlaXXXXXXXTAMIN
Take 1 tableXXXXXXXXXX/2023
B-12) 1,000 mcg tablet
mouth daXXXXXXXIQUIS 5 mg TaXXXXXXXXXX/XXXXXXXXXXidine 20 mg tablet
Take 1 tableXXXXXXXXXX/XXXXXmouth daXXXXXXXXXXXyurea 500 mg capsule Take 1 capsule by 60 capsuXXXXXXXXXX/XXXXXmouth 2 (two)
times daXXXXXXXXXXXprost 0.005 %
Place 1 drop XXXXXXXXXX/2023
ophthalmic solution
XXXX eyes every
evening before
dinXXXXXXXXartan 25 mg tablet
Take 1 tableXXXXXXXXXX/XXXXXmouth daXXXXXXXXXX/XXXXXXXXXX acid/herb
TakXXXXXmoXXXXXXXXXX/2023
XXXXXXXXXXIN D3
COMPLETE OXXXXXXXXXXXtatin 10 mg tablet
Take 1 tableXXXXXXXXXX/XXXXXmouth nightly.
Indications:
combination XXXXXXXXXXXXXXXXXXMADoL 50 mg tablet
Take 1 tableXXXXXXXXX/XXXXXmouth every 6 (six)
hours as neededXXXX pain.
OBJECXXXXXXitXXXXXXXX23/23 XXXXXXXX23/23 XXXXXXXX23/23 XX00
BP:
108/59
110/59
10XXXXXPulse:
66
6XXXX
Resp:
15
1XXXX
TXXXXXXXmpXXXX
SpO2:
93%
96%
XXXXXXeight:
HeiXXX:
Gen: XXXXXXXoomed, no aXXXXXXXXtress

PDF PXXXXX
HXXXXXXXXXcXXXXXXXclXXXeXXXXm
XXXXXXsXXXXXXXXXXXXXXXiXXinXXXV: rrXXXXX XXXXX
Lungs: no incrXXXedXXXX,XXXXXXXbdomen: dressings W small amouXXXXXXXXXXXXXXXXXXXXXXXaining, jp drXXXXXXXXXXXXXXXXXXXX
fXXXd,XXXXXXXXXXXXtended, soXXXXXXXXaXXXXXXXXgXXXtyXXXt: BXXXXXXXXanosXXXXXXXXubbinXXXXX eXXXa; BXXXXX XXXXaXXXXn:XXXXXXXXXXXXXturgor, no obXXXXXXraXXXXXXXXXechiXXXXXXXeXXXXX
NXXXX: XXXXXXXXXXXXXXXmeXXXXXXXXXXXXXflXXXXXXXXuXXXXX handsXXXXXXXiXXXXs feeXXXXX
PXXXXX AlerXXXXXXXXientedXXXXXXXXXXXXXaXXXXt
LABS
RXXXXtXXXbXXXXXXXX/23/23XXX37
HGBXXXXXXLXXXXXXXX/23/23
Reference
10:37
Range &
XXitXXXXXXXXXXXXXX BloodXXXX4
XXXXXXXXterial
35.0 - 45,0
38.7
XXXHgXXXXXXXXterial
80.0 105.0
290.0 (HH)
XXXXg
XXXXXXXXterial
22 26
21 (L)
mXXXXXXSoXXXXXXXXXXXXXXXod Gas
138 - 146
141
XXXXXXXXXXXXXXXXXld Gas
3.5 4.9
3.8
XXXXX
XXXXXXXXXXXXal POC
23.0 - 27.0
22.0 (L)
mmol/L
XXXXXXXXXXXXal POC
95 98%
100 (H)
(HH): Data is critically high
(L): Data is abnormally low
(H): Data is abnormally high
LXXXXXXXX/29/23
Reference
14:21
Range &
XXXts
WBC
3.6 10.2
6.1
10^3/uL

PDF XXXe 9
RBC
(Based on
2.52 (L)
documented
legal sex)
4. 10-5.30
1XXX/uL
HGB
(Based on
10.6 (L)
documented
legal sex)
11.9-15.XXX/dL
HCT
(Based on
32.0 (L)
documented
legal sex)
37.4-XXX3 %
MCV
82.0 - 99.0 fL
127XXX(H)
MCH
27.0 - 33.0 pg
42XXXXH)
MCHC
32.0 - 36.0
33.XXX/dL
RDW
11.0 - 15.0 XXX2.1
PLT
150 - 450
198
1XXX/uL
MPV
9.8 - 12.7 fL
9XXXXXXXXXXXXXXed RBCs
0XXXXXXXXXXXXXXXXXXXbsolute
1.1 6XXXXXXXXXXXXXXXXl Count
10^3/uXXXX): Data is abnormally low
(H): Data is abnormally high
XXXXXXXX9/29/23
Reference
14:21
Range &XXXXXX
Sodium
133 146
142
XXXXXXXXXtassium
3.5 5.1
4.6
XXXXXXXXhloride
98 107
106
XXXl/L
CO2
21 31
27
XXXXXXXCalcium
8.3 10.5
9.6XXX/dL
Bun
7 - 25 mgXXXXXXXXXXatinine
0.60 1.30
0.84
mg/dL

PDF XXXXXXX
Glucose
70 - 100
106 (HXXXg/XXXXLT (SGPT)
9 - 43 uniXXXL
XXXXST (SGOT)
13 - 39 uniXXXXXXX
Albumin
3.5-5.0 - gXXXXXXXXXXXXXXXXXXXXsphatase
34 - 104
50
XXXXXXXXXXXXXXXin Total
0.2 - 1.2
0.XXXXXXXXXXXXX Protein
6.4 - 8.3 gXXXXXXXXXnion Gap
4 - 13 mXXXXXX9
eGFRcr (CKD-EPI 2021)
>=60
70
mL/mXX/1X73
XXXXH): Data is abnormalXXXhiXXXXXGXXX0XXXXXXXXXXXXXXXXXXXXXXXXX
IXXXXXGXXX0/14 CXR
FINDINGS/
IMPRESSION:
1.XXXXXXX opacity in the peripheral righXXXXwer lobe may reXXXXXXXXXXXlectasis, XXXXXXXXXXXeXXXXXXXXscarring oXXXXXXXXXneumonia in the proper clinical settXXXXXXXXXXXXmothoXXXXXXX XXXXXXXXeffusXXXXXXXXXXXXXXXXXart size. AtheroscXXXXXXXXXXrtuosityXXXXXXXXXXXXXXic aorta.
3. NXXXXXXX XXXXXXXXXXXormality. There is an IVC XXXXeXX
XXXXXXXXABD/PELV
Again seen is a XXXXXXxXXXXvic mass at and slightly to the right of midline, now measuring
11.4 cm anteroposterior, 10 cm transverse, and 11.5 cm craniocaudal, previously 14.5 X 11.4
X 11.2 cm when using similar measurement technique. Although there is interval decrease in
size, this appears to represent decreaseXXXXXXXXXXXXXXXXomponent, as there is incXXXXXng
muXXXXXXdXXXXXXXXXXdularXXXXXXXXXXickening compared to pXXXXXXX imaging. Finding is
consisteXXXXXXX XXXXXXXXneoplasm. DeXXXXXXXXXXXs effect on tXXXXXXXXXXXXXXXXXiac vein is
decreased compared to thXXXXXor study.
IMPRESSION:
1. Complex cystic anXXXXlid massXXXXXXe pelvis as detailed above, suspiciXXXXXXX XXXXXXXXneoplasm. Since pXXXXXXX imagiXXXXXhXXXXXXlXXXXXXXXXXdularXXXXaXXXXXXXXXXickening appear
increased.
2. AsymmetXXXXXXX smallXXXXXXt common and eXXXXXXXXXXXac veins, consisteXXXXXXX sequela oXXXXXXXXthrombus. No acuXXXXeXXXXXXXXthrombus is identified.
ASSESSMENT/PLAXX
is a X0 y.o. F with a history of esXXXXXXXXXXXXXXocXXXsiXX DVT,XXXXXXXXXXC filter,
B12 defXXXXXXy XXXXXX,XXXXvic mass, aXXXXXXXXXX/23/2XXXXX/p exlap, R oophrecotmXXXXXXXXXXXntectomy.

PDF PagXXXXXs/p exlap, R oophrecotXXXXXXXXXXXentectomy
- management per gyn onc
H/o eXXXXXXXXXXXXXXbocytosis
- XXXXXXXXXXXdroxyurea
- fXXXXXXr. EiXXXr
XXo DVT, PE, IVC filteXX- holdXXXXXAP, NSAID 2/2XXXXXXXX bleeding concerns
- pt to f/u W IR as outpatXXXXXXXXXXXXXXXXXXr removal
B 12 deXXXXXXcy anemia
- contXXXXXXXX
Glaucoma
- XXXXXXXXXXXtanoprost
Hospital Medicine CXXXXXXXXXX0XXXXXXXXXXXXXXXophylaxis: scd
CVC/FoleyXXXXs
AM LXXXXXXXXXIV fluXXXX Yes
Tele: No
Expected Discharge Date: 3 days
Provider, ExtXXXXXXXXX10/6/2023 13:43
DocXXXXXXXXX10/6/2023 1:43 PM by
Progress Notes Last 48hrs (NoXXXXXXXXXX0/23/2023 1:59 PMXXXXXXXXXX0/25/2023
1:59 PM)
NoXXXXXXXXXX0/23/2023 1:59 PMXXXXXXXXXX0/25/2023 1:59 PM
Progress Notes byXXXXXXXXXX0/25/2023 9:48 AM
Version 1 of 1
Author:
PA-C
XXXXXXXXXXXXXXXXXXX Oncology
Author Type: Physician AssistanXXXXXXXXXX0/25/2023 9:54 AM
Date of XXXXXXXXXX0/25/2023 9:48 Status: Cosign Needed
AM
Editor:
PA-C (Physician Assistant)
Cosign Required: Yes
Gynecologic Oncology Progress Note
SubXXXXXXX:
SurgeXXXXXXXXXX0/23/2023
POD: 2 Days Post-Op
Surgery: ProceXXXXXXXXXXXXXXXXXXXXXXaparotomXXXXXXXXXXXXXhoXXXXXXy, peXXXXXXXXXXXXXXXXXXXXXXXXXXdeXXXXXXXXXXXXXXXXXXXXXXXXentectomy, right ureterolysis, extensive lysis of adhesions
Interval History:

PDF Page 12
Patient sitting up in chair, family atXXXdsXXXXXXXX, XXXXrile. LabXXXtable,XXgb 8.5. JP with
350cc oXXXXXXXXXXSSXXXXXXXt. Voiding spontXXXXXXXXXXXXequate XXXXXXome nausea this
morning but reliXXXXXXith Zofran. OXXXXXXXXXXXXXXXating dieXXXXXXieXXXXatus. Pain overall well
controXXXXXXXth PO meds. Due to ambulate.
Objective:
XXXXduled Meds:
Current Facility-AdmXXXXXXXXXXXeXXXXXXXXXXMedication
Dose
Route
XXXXXXXXXXXXXtaminophen
650
Oral
XXXXXXXy
(TYLENOL) tablet mg
650 mg
[START ON
10 mg ReXXXXXXXXXX10XXXXXXXXX
bXXXXXXXX
(DULCOLAX)
suppositXXXXXXXXXXXXXXocobalamin
1,000
Oral
Daily
tablet 1,00XXXXXXXXXXfamotidine
20 mg XXXXXXID
(PEPCID) tabXXXXXXXmgXXXXXXXn (porcine)
5,000
Subcutaneous
TID
injection 5,000
UnXXXXXXXXXXXydroxyurea
500
XXXXXXID
(HYDREA)
mg
capsuXXXXXXXXXXXatanoprost
1 XXXX Both XXXXXXXM
(XALATAN) 0.005
% ophthalmic
solution 1 drop
pravastatin
20 mg OralXXXXXXXXX(PRAVACHOL)
tabXXXXXXXXXXXXXXa-docusate
2
XXXXXXXXXXPERICOLACE)
tablet
8.6-50 mg per
tablet 2 tablet
Continuous Infusions:
Current Facility-AdmXXXXXXXXXXXeXXXXXXXXXXMedication
Dose
Route
XXXXXXXXXXXXXXXXed Ringers
IV Infusion
CXXXXXXXXXXXXXXXXed Ringers
IV Infusion
ContiXXXXs
XXXXXXXXXXXXXXXXXXXe-XXXXXXXl XXXXXXXXXXXorXXXXXXXXXXXXXXXnhXXXXXXXXXXXXXXXnhXXXXXXXXXXXXXROXXXXXXXXXXXXXXclXXXXXXXXXXXndansetron (PXXXXXXXXXXXXXXXseXXXXXXXXXXXXXXXXXylXXXXXXXXXXXXXXXXorXXXXXXXXXXXimXXXXXXXX, traMADoL
Allergies: Patient has no known aXXXXXXXXXXXemperatuXX: [97.8 °F (36.6XXC)-99.1 °F (37.3 XX)] 97.8 °F (36.6 °C)

PXXXXXXXXXX
Heart Rate: XXXXXXXXXXXXespirations: XXXXXXXXXXXXXXod Pressure: (109-135)((41-XXXX125/54
SpO2: [91 %-XXXXXXXXXXXXXtaXXXOutput:
I/O last 3 completed shifts:
In: 1708.7 XXXX.:840; IXXXXX68.7; Blood:600]
XXXXX2250 [Urine:1650 DXXXXXXXXXXXXXysXXXXXXXam:
GenXXXXX This womaXXXXXXXXno distress appearing comfortabXXXXXhe isXXXXXXXXnd orXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXo XXXXXioXXXXXEXXXXXXXXXXXXXXXXs memXXXXXX,XXXXXhrushXXXXXXXXXXXXXXXXXXXXXuscultation bilateXXXXXXXXXXXXXXXXXXXXXXX eXXXXXXXXXXXXXXdiovascular examinatiXXXreveals RRXX witXXXt XXXXXXXub.
AbdomeXXXXXXXXX, XXXXXXXXXXXXondistendXXXXXXXXXXXXXXXXXXplenomegaly. She has no
eXXXXXXe XXXXerniXXXXXXX oXXXXcites. + BS X 4. JP XXXXXXXXXX XXXXXXXXXXXExtremities aXXXXXXXXutXXXXXXXXs, cXXXXXngXXXXXdXXXX
Neuro exam XXXXXXXXlyXXXXXocal.
Wound Description: midline incision island dressing removed. Staples intact.
Data Review:
HXXXXRXXXnXXXXXXXXaXXXXXXXX2XXXXXXXX2XXXXXXXX23
10/25/23
1037
0438XXX57
0517
WBC
--
9.0XXX.8*
9.1
HGB
8.8*
6.4*XXX0*
8.5*
PLT
--
117*XXXX*
128*
ChXXXXRXXXnXXXXXXXXaXXXXXXXX23
10/25/23XX438
0517
XA
138
142
K
4.6
3.9
CLXXX8*
108*XXX2
25
27XXXXXXXXXX
CREATININEXXXXXXX.70
GLUCOSEXXXXXXX09*
CALCIUM
8.7
8.0*
CoagulatiXXXXRecent Labs

XXX XXXXXXXXLXXXXXXXX/XXXXXXXX/23
10/25/23
043XXX257
0517
PLT
117XXXXXXXXXXXXXumXX Markers:
CA 125
Date
Value
Ref RXXXXXXXXXXs
03/31/2023
35.0
0.0 - 35.0 UniXXXXXXXXXXl
01/12/2023
59.0 (H)
0.0 - 35.0 - Units/mL
Final
Last 3 Weights:
Wt Readings from Last 3 XXXXXXXXrs:
10/23/23
59.2 kg (130XXXXXXXXoz)
10/06/23
58.1 XXXXXXXXlb)
09/29/23
59.4 kg (130 lb 14.4 oz)
XXsessmeXXXXXX y.o. female POD #2 after PrXXXXXXXXXXXXXXXXXXXXXXy laparoXXXXXXXXXXXXXopXXXXXXtomy,XXXXXXXXXXXXXXXXXXXXXXXXXXphXXXXXXXXXXXXXXXXXXXXXXXX omentectomy, right ureterolysis, extensive lysis of adhesions
Patient Active Problem LisXXXXXXXXXXs
CelluXXXXXXXXXXXXXXXXXXXXn XXXombosXXXXXXXXXXXXfemoral vein ofXXXXXXXXXer extXXXity (CMSXXXXXXXXXtXXXXXXXXary embolism wiXXXXXXXXXXXXXor pulmonalXXXXXX-XXXX
PelXXXXXXss in female
Presence of IVC filter RETRIEVABLE
Preop teXXXXXXXXXXe blood loss as cause of poXXXXXXative anemiXXXXXXXXXXXXXXrombocytosis (CMS-HCC)XXXXXXXXXC: Pathology Pending, frozen c/w HGSOC. Will need to be presented at tumor boardXXXXn final paXX resulted
GI: regular diet, - flatusXXXXXXtient nauseXXXXXXXXXXXXXXweXXXXotocol.
Pain: contXXXXXXXXXXXXXcetamXXXXXXXXand TXXXXXXXXXXXXXX pXXXXXXaXXs:XXXXXXXXXXXXXXXXXXXXXXXX XXXX and BP
Pulm: encourage IS and deeXXbreathing
GU: Voiding, adXXXXXXXXXXXXXXX pXXXXylaxis: SCDs, trXXXXXXXn to lovenox starting tomorrow morning. Will need AXXXXonXXXXXXXXXX: XXXble WBC, hgb staXXXX s/pXXXXXRBC oXXXXXXXXXXX transfusion needs at this time.
Electrolytes: replete as needed per protocol
Activity: ambulate several times a day, encourage IS 10x/hr while awake

PDF Page 15
Disposition: anticipate discharge home possibly 2-3d. PT XXXXXXXXXXXXXSAR placement
upon d/c
Case discusXXXXXXXXXXXXXXXXC
Gynecologic- Oncology
Progress NoteXXXXXXXXXXat 10/24/2023 7:32 AM
Version 1 of 1
Author:
PXXXXXXXXXXXXXXXXXXXlogy Oncology
Author Type: Physician AssiXXXXXXXXXXd: 10/24/2023 10:32 AM
DateXXXXXXXXXXe: 10/24/2023 7:32 Status: Cosign Needed
AM
Editor:
PA-C (Physician Assistant)
Cosign Required: Yes
Gynecologic Oncology Progress Note
Subjective:
SXXXXXXXXXXe: 10/23/2023
POD: 1 Day Post-Op
Surgery: PXXXXXXXXXXXXXXXXXXXXXXry laparXXXXXXXXXXXXXooXXXXXXctomyXXXXXXXXXXXXXXXXXXXXXXXXXXmpXXXXXXXXXXXXXXXXXXXXXXXXc omentectomy, right ureterolysis, extensXXXXXXXXX of adhesions
Interval HistXXXXXXXXXXXXXXesting XXXXXXXXVSXXXafebrile. Hgb this AXXXX 6.4, 1u PRBC ordered.
States she has bXXXXfeeling "weak". JP drain with 200cc outpuXXXXXXXXXXXXXXXXXXXXXXX
gXXXXXXXXXXXXXXXXXXull breakXXXXXXitXXXX nausea. Pain well controXXXXXXXth PO tylenol. FoleXXXXXXXXXXXX urine output XXXXXXXXXXXXXXppears yellow this AM.XXXXXXXXXyet aXXXXXXXX 2/2
weakXXXXXXdenies SOXXXXXXDeniXXXflatus or BM.
ObjectivXXXXcheduled Meds:
Current Facility-XXXXXXXXXXXdXXXXXXXXXXns
Medication
Dose
RouXXXXXXXXXXXXXacetaminophen
650
OrXXXXXXXaily
(TYLENOL) tablet mg
650 mg
[START ON
10 mgXXXXXXXXXXceXXXXXXXXX23XXXXXXXXdyL
(DULCOLAX)
suppoXXXXXXXXXXXXXXyanocobalamin
1,000
Oral
Daily
tablet 1,000 mcg
mcg

PDF Page 16
[Held by Provider] 40 mg SubcuXXXXXXXXXXilXXXXXXXparin
(LOVENOX)
inXXXXXXXXXX mg
famotidine
20XXXXXXal
BID
(PEPCID)XXXXXXXXXXXmg
hydroxyurea
XXXXXXal
BID
(HYDREA)
mg
cXXXXXXXXXXXmg
latanoprosXXXXdrop BXXXXXXXs
QPM
(XALATAN) 0.005
% ophthalmic
soXXXXXXXXXXXop
pravastatin
20 mg XXXXXXXXXtly
(PRAVACHOL)XXXXXXXXXXXXXXsenna-docusatXXXXXXXXXXID
(PERICOLACE)
tablet
8.6-50 mg per
tablet 2 tablet
Continuous Infusions:
Current FacilityXXXXXXXXXXXeXXXXXXXXXXons
Medication
Dose
RoXXXXXXXXXXXXXXXXctated Ringers
IV InfusiXXXXXXXXXXXXXXXXctated Ringers
IV InfusiXXXXXXXXXXXXXXXXctated Ringers
IV Infusion
CXXXXnuXXXXXXXXXXXXXXXXXXXcaXXXXXXXntXXXXXXXXXXXL)XXXXXXXXXXXXXXXipXXXXXXXXXXXXXXXipXXXXXXXXXXXXX HXXXXXXXXXXXXXXmeXXXXXXXXXXXe, ondansetroXXXXXXXXXXXXXXXndXXXXXXXXXXXXXXXXXyvXXXXXXXXXXXXXXXXocXXXXXXXXXXXe,XXXXXXXXcone, traMADoL
Allergies: Patient has no knoXXXXXXXXXXXs.
TempeXXture: [XX.1 °F (36.2XXXXXXXXXX°C)
Heart Rate:XXXXXXXXXXXX7
RespirationXXXXXXXXXXXXXXBlood Pressure: (92-117)/(XXXX9) 103/43
SpO2: [90 %-XXXXXXXXXXXX$ O2 Flow Rate (L/min): [1 L/min-2 LXXXXXXXXXXXXX
IXXXke/Output:
I/O last 3 completed shiftsXXXX: 3628.7 [P.O.:360;XXXXXXXXXXXX; IV Piggyback:50XXXXXt: 1475 [Urine:675; Drains:30XXXXXXXXXXXXX
PXXXXXXX Exam:
XXXXXal: This wXXXXXXXXin no distress appearing comforXXXXX, sheXXXXXXXXt andXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXy XXXXXesXXXXX.XXXXXXXXXXXXXXXXcous XXXXXXnXXXXXo thrXXXXXXXXXXXXXXXXXXXXXo auscultation bilaterallXXXXXhXXXXXXXXXXesXXXXXXXXXXXXXXCardiovascular examinXXXon revealsXXRR, XXXhout S3 or rubXXXXXXXPage 17
AbXXXXXXXXXsoXXXXXXXXXXXXr, nondisXXXXXXXXXXXXXXXXXXatosplenomegaly. She has XXXXXXdeXXXXof hXXXXXXXmassXXr ascites. + BS X 4. JP drain with SSXXXXXXXtXXXXXXXXXXXied
ExtremitiXXXXXXXXitXXXXXXXXnosiXXXXXubXXXXXoXXXXema.
Neuro eXXXXXXXXroXXXXXnonfocal.
Wound DescriXXXXXXXXidline incision with island dressing in place, stained wXXXXXXXXt pink
drainage
Data RevieXXXXEXXXRXXXXXXXXbXXXXXXXX/23/23
10/2XXX3
1037
0XXX
WBC
--
9.0XXXB
8.8*
6.XXXXLT
--
117XXXXeXXXRXXXXXXXXbs
LabXX0/24/X3
043XXNA
138XXX4.6
XXX108*XXXXXXXXXXN
16
CXXXXXXXNE
0.7XXXXXXXSE
11XXXXXXXXXXX8.7
CoaguXXXXoXXXRXXXXXXXXbs
LabXXX/24/23XXXXXXXXXXXXX*
XXmor Markers:
CA 125
Date
Value
ReXXXXXXXXXXatus
03/31/2023
35.0
0.0-35.0 - XXXXXXXXXXinal
01/12/2023
59.0 (H)
0.0-35.0 Units/mL
Final
Last 3 Weights:
Wt Readings from LastXXXXXXXXnters:
10/23/23
59.2 kg (XXXXXXXX.2 oz)
10/06/23
58XXXXXXXX28 lb)
09/29/23
59.4 kg (130 lb 14.4 oz)

PDF Page 18
AsseXXXXXX:
80 y.o. female POD 1 afteXXXXXXXXXXXXXXXXXXXXXXatory laXXXXXXXXXXXXXhtXXXXXXorectXXXXXXXXXXXXXXXXXXXXXXXXXX lXXXXXXXXXXXXmXXXXXXXXXXXtric omentectomy, right ureterolysis, extensive lysis of adhesions
Patient Active ProblemXXXXXXXXXXnosis
CXXXXXXXXXXXXXXXXXXXX vXXX throXXXXXXXXXXXX of femoral veiXXXXXXXXX lower extremity XXXXXXXXXXXXXXXXXXlmonary embolisXXXXXXXXXXXXXte cor pulmXXXXXX(XXXXHCC)XXXXXXc mass in female
Presence of IVC filter RETRIEVABLE
PreoXXXesXXXXXXXXX:
ONC: Pathology Pending, frozen c/w HGSOC. Will need to XXXXXesented at tumor bXXXX
when finaXXpath resulted
GI: regularXXXXt, - flatus
Pain: XXXXXXXXXXXXXth AcXXXXXXXXhen aXXXXXXXXXXXXXXn
XXXXXXpXXlaxis: PeXXXXXCV: normalXXeXXXXrate and BP
Pulm: encourage IS andXXeep breathing
GU: FolXXXXXXXXXXXXXXX
DVT prophylaxis: SCDs, hold chemoprophylaxis XXXiXXXXternoon hXXXHeXXX stable WBC,XXXX to 6.4, 1u PXXXXXXXXXXX for transfusioXXXWill recheck hgbXXXXXXXXXXXXoon
Electrolytes: replete as needed per protocol
Activity: ambulate several times a day, encourage IS 10x/hr while awake
Disposition: anticipate discharge home possibly 2-3d
Seen with dr
PA-C
Gynecologic Oncology
ProgressXXXXXXXXXXMD at 10/24/2023 8:00 AM
Version 1 of 1

PDF Page 19
Author:
MD
Service: Hospitalist
Author Type: XXXXXXXXXXFiled: 10/24/2023 10:10 AM
XXXXXXXXXXrvice: 10/24/2023 8:00
Status: Signed
AM
Editor:
MD (Physician)
NMRMG Hospitalist Progress Note
Patient name:
Room:
DaXXXXXXXXXXssion: 10/23/2023
Primary care physician:
MD
Daughter assisted with Urdu translation per pt preference
CC / Reason for visit: gen XXXXXXXXXXX gyne onc surgery
InXXXval Events:
- HGB 6.4XXXXs AM. 1 unit pRBC XXXered
- repeat cbc planned for early afternoon
S:
- she XXXXsome post-op paXXXXXXXXXas soXXXXXXXXness. No vomiting.
O:
No Known AllXXXXes
Scheduled Meds:
Current FacilXXXXXXXXXXXtered Medications
Medication
DoseXXXXXXXXXXXXXncy
acetaminophen
65XXXXXXX4x Daily
(TYLENOL) tablet mg
650 mg
[START ON
1XXXXXXXXXXl
XXXXXXXXX6/XXXXXXXXsacodyL
(DULCOLAX)
sXXXXXXXXXXXXXXmg
cyanocobalamin
1,000 Oral
Daily
tablet 1,000 mcg
mcg
[Held by Provider] 40 mg SuXXXXXXXXXX
DXXXXXXXoxaparin
(LOVENOX)XXXXXXXXXX 40 mg
famotidineXXXXXX Oral
BID
(PEPCXXXXXXXXXXX20 mg
hydroxyurXXXXXX
Oral
BID
(HYDREA)
mXXXXXXXXXXX00 mg
latanopXXXX
1 droXXXXXXXEyes
QPM
(XALATAN) 0.005
% ophthalmic
solution 1 XXXXXXXXXXXage 20
pravastatin
20XXXXXXXXXNightly
(PRAVACXXXXXXXXXXXXXX mg
senna-docXXXXXXXXXXal
BID
(PERICOLACE)
tablet
8.6-50 mg per
tablet 2 tablet
Continuous Infusions:
Current FaciXXXXXXXXXXXsXXXXXXXXXXcations
Medication
DosXXXXXXXXXXXXXXXXy
Lactated Ringers
IV InXXXXXXXXXXXXXXXXs
Lactated Ringers
IV InXXXXXXXXXXXXXXXXs
Lactated Ringers
IV InfusiXXXXonXXXXXXXXXXXXXXXXXXXenXXXXXXX- XXXXXXXXXXXPAXXXXXXXXXXXXXXXt,XXXXXXXXXXXXXXXE,XXXXXXXXXXXXXINXXXXXXXXXXXXXXneXXXXXXXXXXXamide, ondansXXXXXXXXXXXXXXX**XXXXXXXXXXXXXXXXX pXXXXXXXXXXXXXXXX, XXXXXXXXXXXazXXXXXXXXethicone,XXXXXXXXL
VitaXXXXXXXX3/23 1XXXXXXXX3/23 2XX0
10/24/23 0344
BP:
108/51
(!) XXXXX4
(!) 103/4XXXXlse:
61
62
XXXXesp:
16
16
16
TeXX:
98.1 XX (36.7 XX)
98.8 XX (37.1 °C)
98XXXXXXX37.2 ° °C)
TempSrXXXXral
Oral
Oral
XXXXXX92%
98%
97XXXeigXXXXXXXXht:
Gen - PleaXXXXXXXX nXXXXXXXXXXXXXXXXXXXonXXXXXcXXXXXXXXXXX XXXXX/apXXXXXiXXXXXXXXXXXXXXXstXXXXuXXXXmbrXXXXXXXXXXXXXXX -XXracXXX midlXXXXXCXXXXXRR,XXXXXXXXXXXXXXXXXXXXXar to auscultatioX XiXatXXXXXXXXXX w/r/r, nml eXXXXXXXn room air
AXXXXXXXXXXmiXXXXXXXXstension. Incision dressed with minimaXXXtrXXX XXXough, XXXXX+BS
XXXXXXXX edema orXXXaXXXXs, distal XXXXXXXX XXXXwell pXXXXXXXXSkin - noXXXXXXXXXXXXXro - XXXXXX XXXXntXXXo XXXmor
LabsXXXXCXXXNXXXXXXXX XXXXXXXX
10/23/23
1XXX4/23
103XXX438
WBC
--
XXX
HGB
8.8*XXX4*
PLT
-XXXX7*
CMP
RecentXXXbXXXXXXXXage 21XXab
10X24/23XX438
NAXXX8
K
XXX
CL
XXXXXXXXXX5
BUN
XXXXXXXTININEXXXXXXXLUCOSE
117*
CXXXXUM
8.7
Pending Labs
OrXXXXXXXXent Status
CYTOLOGY, BODY FLUID
In process
SURGICAL PAXXXLOGY
In process
RBC Prepare and Crossmatch, 1 Units
XXXliminary result
RBC Prepare and Crossmatch, 2 Units
XXXXXXXnary result
Imaging:
None this eXXounterXA/P:
is a 80 y.o. F with a hiXXXXXXXXXXXXXXtiXXXthXXmbocyXXXXXXXXXX, PE s/p IVC
filtXXXXXX2 XXXXXXeXXXXanemia, pelXXXXXXXXXXadmitXXXXX0/23/2023 s/p exlXXX RXXXXXXXXXXXy,
LOAXXXXXntectomy.
s/p exlXXX RXXXXXXXXXXXy, LOA, omentectomy
- management per gyn onXXXXXXe blood loss anemia superXXXXXX onXXXXXXXXX anemia
XXXXansfuse 1XXXit pRBC
- trend cbc RepeatXXXXXXXXXXXXXXXn
- anticoagulation on XXXXXXXXXXXXXXtial thromboXXXXXXXXXXXontinue hydroxXXXXXX- f/u wXXXXXXEisner
XXXXXXXXXXPE
Hx of IVC filXXXXX hold AC, AP,XXXXXXXX/2 post op bleeding concerns acutely. Reassess pending cXXXical
courXX and HGB trend
- pt to eventually f/u W IRXXXXXXXXXXXXXXXXXX IVC filter removXXXXXX2 deficiency aneXXXXXXXXntinue B12
GXXXXXXXXXXXontinue latanoprost
Hospital XXXXXXXXXXhecklist 10/2XXXXXXXXXXXXXXXe 22
DVT prophylaxis: SCDs
CVC/Foley: +XXXety XXXX-op / no CVC
AM XXXXXXXXX - post-op
IV flXXXX: Yes - post-op
Tele: No
ExpecXXX Discharge Date: TBD pending post op course. Hear at least one moXXXnight to
monitor HGB
MD
NMRMG HospitaXXXXXXXele):
(Fax):
Therapy Note XXXXXXXXXXXXXXXXXX (XXXXXXXXXXherapist) 10/25/2023 09:41 RehaXXXXXXXXXXXXXXXXces
Physical Therapy Initial EvaluationXXXXXXXXXXAME:
DOB: 12/15/1942 MRN:XXXXXXXXXXXXXXXXXXXXMEDICAID XXXXXXXXXXXXXXXlan: MERIDIAN HEALTH PLAN OF IL /
Product Type: XXXXXXXXssion Date: 10/25/23 Session Time: 0928
Patient Received: Supine in bed
Medical Lines/Equipment: (none)
History of Present IllnessXXXXXXpXXXXagnosis: pelvis mass
Pertinent Past Medical/Surgical History:
Past Medical HistXXXXXXiagnosis
DaXXXXXXXXXXXXsential hypertensioXXXXXXXXXXXXXXntXXX thromXXXXXXXXXX(XXS-XXXXXXXXXXXXXXXXXXXXXXXXXnarXXXhromboXXXXXXXXXXXXXX-XXXXXXXXXXXXXXXXXXXXXXXamin B 12 deficiency
PasXXXXXXXXXl History:
ProcedXXXXXXXXXXXXXXXDXXXXXXXXXXNXXXXXXXXXXXXXXXXXXXXXXploratorXXXXXXXXXXXX, XXXXXXoophoXXXXXXXXXXXXXXXXXXXXXXXXXXrtXXXXXXXXXXXXXXXXXXXXXXXXagastric omentectomy, right urXXXXXlysis wXXXXXXXXXXXXrXXXXXXXXXXXXXXCXXXXXXXXXXXRXXXXXXXXXXNE MXXXXXX0XXXXXXXXXXXRXXXXXXXXXONE MARROW 5/31/2023 CDH INTXXXXXXXXXXXXXXXXXXXXIXXXXXXXXXXPLACXXXXXXXXXXXXXXXXXXXXIXXXXXXXXX PLACXXXXXXXXXXXXXXXXXXX INTERVENTIONAL LABS

PDF Page 23
RUE weight bearXXX: No restrictions
LUE weight bearXXX: No restrictions
RLE weight bearXXX: No restrictions
LLE Weight Bearing: No restrictions
Precautions: Fall
Interpreter Use
Free and Confidential Interpreter Offered: Yes
Interpreter Name and ID: dtr requested to interpret but despite several requests for dtr to
walk wiuth pt, dtr remained in room on phone. pt was able to understand general english for
communication
Topic of interpretation : General communication, Assessment
Patient Declining Hospital Interpretation Services: Yes
Subjective
Subjective
PT SubjecXXXXXReport: "I feel tired"
Home Environment:
Type of Home: Apartment/condo
Home Layout: (lives on second level and dtr reports no elevator but dtr is from out of town)
Lives With: Alone
Receives help from: Family
Needs Assistance With: Meal preparation, HousehXXX chores, Driving, Med management,
Shopping, XXXXXXXXXXXXXlation, Bowel/Bladder, Finances, Dressing, Transfers
Home Equipment: Cane (straight) (requests a walker for home use)
Prior Level Of Function:
Prior Function: home ambulation
Prior Function - Home Ambulation: Modified independent
Braces/Equipment/Devices
Patient used prior to hospitalization: Assistive device(s)
Assistive Devices: Single point/straight cane
Pt lives alone in second story apt with family periodically coming by. Has stairs and no
elevator per family report. Uses SC PTA aXXXXamXXXXdrivesXXXX
Pain:
Pain: Yes
Pain Intervention(s): Rest
PXXXXXXXXXXused: 0-10
Pain Score:XXXXd not rate XXXXXXXaXXXXocation: Abdomen
Pain Quality: Aching
Patient Behavior: Calm
Is patient willing to proceed?: Yes
Objective

PDF Page 24
OBJECTIVE
Vision: WFL
PT CoXXXXXXXX Orientation: oXXXXXXXXto person and oriented to place XXXXXXXXXXXXXXXXXXXXXXXXod awareness XXXXXXety precautions
Speech: Intact
Behavior: Cooperative
SeXXXXioXXXXXXXXXXXXsXX
SXXXX UnremarkXXXe
UE: AROM appearXXXXXXXXX XXXXXXXd pt moveXX UXXXXasint graXXXy
LE: AROM appears WFL AXX observed pt move B LE agasint gravity
Balance: Sitting static: Good, Sitting dynamic: Good, Standing static: Good and
Standing dynamic: Fair plus with walker
Posture: SitXXXX PostXXXXXXXrXXXXXXXXd and rounded shoulder and StanXXXX PostXXXXXXXrXXXXXXXXd and rounded shoulder
Coordination: NT
Mobility:
Bed Mobility: Bed Mobility: (pt up in chair upon entering)
Transfers: Transfer: sit to stand, stand to sit
Equipment Used: Rolling Walker
Sit to Stand: stand by assist
Stand to Sit: stand by assist
Gait: Distance Ambulated (ft): 125 ft
Ambulation Device: Rolling Walker
Ambulation Assistance Level: contact guard assist
Gait Assessment: pt sitting in chair upon entering. pt sit-stand with RW and SBA. pt CGA for
ambulation with RW. requested to ambulated beyond room. pt slow and needs incrased time
but able to complete distance. question if pt able to manage I at home with ADL etc. per CM
notes, pt has assist from family but dtr today requested rehab at DC.
Number of Assist: 1 staff mXXXXXXXXXXXXXXXXXXXs:
Supplemental Oxygen Supply:
Outcome Measures:

PDF Page 25
Six Clicks:
How much difficulty does the patient currently have turning over in bed (including adjusting
bedclothes, sheets and blankets)?: None
How much difficulty does the patient currently have sitting down on and standinXXXX from a
chair with arms (e.g., wheelchair, bedside commode, eitc.)?: None
How much difficulty does the patient currently have moving from lying on back to sitting on
the side of the bed?: A Little
How much help from another person does the patient currently need moving to and from a
bed to a chair (including a wheelchair)?: None
How much help from another person does the patient currenlty need to walk in hospital
room?: A Little
How much help from another person does the patient currently need climbing 3-5 steps with
a railing?:XXXXXXXXXXXXXXXXXX Six XXXXXXXXXXXXXXXXXXXXX1
Therapeutic Exercises:
n/a
Treatment Rendered During Session / Patient Education:
See above comments
End of session position: Up in chair, Call light within reach, All lines intact, Chair alarm on,
Nursing notified
Assessment
ASSESSMENT
Goal Timeline: LOS
Patient Stated Goals: to go home
Goals:
Goal
Progress
Patient will be independent with supine
New goal
to sit transfers.
Patient will be modified
New goal
independent with sit tXXXXXXXXXXXXXXers
with rolling walker
Patient will ambulate 51-100 - feet
New goal
modified independent with rolling
walker
Patient will go up and down 6-10
New goal
stairs modified independent with onXXrailinXXXXXXent is a 80 y.o. female who presenXXXXXXpXXXXcal therapy pelvic mass. Currently, thXXXXXXXXXXXemonsXXXXXXXXXXXXXXXXXXXXXX functional limitations as listed below. The patient
would benefit XXXXXXXXXXXXXXXXkilled physical therapy intervention to improve these
impairments and limitations, maximize safety, progress functional independence and

PDF Page 26
facilitate safe discharge. Patient's prognosis for goal completion is Good as evidenced by
CGA/SBA for mobility with RW. Recommend SAR as pt is not at baseline and was using SC
PTA. However, if pt not quialifed, then home with family assist and RW/HHPT would be rec.
Disc with XXXXXXXXXXXXXXXXrmXXXX: XXXXXXXXXXXXXXXXX Pain, Decreased balance
XXXXXXXXXXXXXXXXXXXXXX: Decreased XXXXXXXXXXXXXXXXXXXXXX, DecrXXXXXXXXXXXXXXXXXXXXXXXXXtair negotiation
Therapy charges were separate and distincXXXXXXXXXXXXXXXXan
PLAN
Physical Therapy Plan of Care
XXXXXXXXXXXXXXXXXXXXXXX
Treatment/InterventXXXXXXXXXXXXXgoXXXXXXXXXXXXt training, ADL training, Balance,
Compensatory technique education, Bed mobility
PT Frequency: 3-5x/wk
Equipment Recommended: Assistive device(s)
Assistive Devices: Standard walker with wheels
Plan PT/PTA Communication: Yes
Discharge Disposition:
Sub acute rehab (SAR pt is notXXXXXXXXXXne as she was ambulatory with SC PTA and now
using RW. if pt does not qualify then home with family assist and HHPT. will need RW for
home at thXXXXXXXXXXso.)
NameXXXXXXX/25/2023
Current IP Meds
(From admission, onward)
Start
Stop Status
XXXXXXXXequencXXXXXXXXX
10/26/23 0900 bisacodyXXXXXXXXified
RXXXXXXXX
10/23/23 1616
(DULCXXXXXXXXppositXXXXXXXXXX10/26/23 0900
enoxaparin
--XXXXXXXXd
SubQ
XXXXXXX4
10/25/23 0955
(LOVENOX)
HOURS
injection 40
mg

PDF Page 27
Start
Stop StatusXXXXXXXXrequenXXXXXXXreXXXXXXX/2XXXXXXXXeparin (porcine)
10/26/23 055XXXXXXXXsed
SubQ
3 TIMES
10/24/23 1635
injXXXXXXXX,000
DXXXXXXXXXX
XXXXXXXX 1430
ALPRAZolam
10/24/23 XXXXXXXXpleted
XXXXXONCE
10/24/23 1409
(XXXXXXXXXlit taXXXXXXXXXX
XXXXXXXX 1200
enoxaparin
10/24/23 1638XXXXXXXXinued SXXXXXXXLY
10/23/23 1245
(LOVENXXXXXXXXXXion 40 mg
(CDH
ENOXAPARIN 40
MG DAILY WHEN
DOSE GIVEN
WITHIN 24
HOUXXXXXXXXus:
DiXXXXXXXXXXXXXX24/23 0900
cyanocobalaminXXXXXXXXensed
Oral
DAILY
10/23/XXXXXXXXtabletXXXXXXXXXXX10/23/23 2100
pravastatin
-XXXXXXXXsed
OraXXXXXXXXX
10/23/23 1616
XXXXXXXXOL)
taXXXXXXXXXX
10/23/23 2100
famotidine
-XXXXXXXXsed
OraXXXXXXMES
10/23/23 1616
(PEXXXXXXXXblet
DXXXXXXXXXXXXXX23/23 2100 senna-docusate
-XXXXXXXXsed
OraXXXXXXXXXX10/23/23 1616
(PERICOLACE)
DAILY
8.6-5XXXXXXXX
tableXXXXXXXXXXX10/23/23 2100
hydroxyureXXXXXXXXsed
OraXXXXXXMES
10/23/23 1616
(HYDRXXXXXXXXY
capsXXXXXXXXXXXXX/23/23 1800 acetaminophen
-XXXXXXXXsed
OraXXXXXXXES
10/23/23 1616
(TYLENOL) tablet
DAIXXXXXXXXg
(8A,XXXXXXXXXXXXXXXXX23 1757
polyviXXXXXXXXXol
-- DisXXXXXXXXoth EyeXXXXXXXXXX10/23/23 1758
(AKWA TEARS)
DAILY PRN
1.4% opXXXXXXXX
solutXXXXXXXXXXXXXXX3/23 1715
diphenhydrAMINXXXXXXXXified
IXXXXXXXXN
10/23/23 1716
(BEXXXXXX)
injection 25 mg
XXXXXXXXXXXtocol
(Adult)
medications)

PDF Page 28
Start
Stop StatuXXXXXXXXFrequeXXXXXXXXXXX
10/23/23 1715
ondansetron (PF)XXXXXXXXed
IVPUXXXXXXRY 6
10/23/23 1716
(ZOFRAN)
XXXXXXPRN
injection 4 mg
(Nausea Protocol
(Adult)
medications)
See attached
printout for fXXXXXXXXed OrdXXXXXXXXXXX
10/23/23 1715
ondansetron-XXXXXXXXfied
OrXXXXXXXXXX
10/23/23 1716
(ZOFRAN-ODT)
HOURS PRN
diXXXXXXrating
tablet 4 mgXXXXXXXXXXXotocol
(Adult)
medications)
See attached
printout for fXXXXXXXXed OrdXXXXXXXXXXXXXX/23/23 1715
metoclopramide
-XXXXXXXXed
IVPUXXXXXXRY 6
10/23/23 1716
(REGLAN)
HXXXXXXRN
injection 10 mgXXXXXXXXXXXotXXXXXXXXult)
mXXXXXXXXXXXXXXXX3/23 1715
prochlorperaziXXXXXXXXied
RecXXXXXXXXX2
10/23/23 1716
(COMPAZINE)
HOUXXXXXX
suppository 25
mgXXXXXXXXXXXotXXXXXXXXult)
mXXXXXXXXXXX
10/23/23 1700
latanoprXXXXXXXXXage 29
XXXXXXXXd
Both XXXXXXXERY
10/23/23 1616
(XALATAN) 0.005
EVENING
% ophthalmic
BEFOXXXXXXXXion 1 XXXXXXXXXXXXXXXX3XXXXXXXX
lactated ringers
10/24/23 1644 VeXXXXXXXXV Drip
CONTINUOXXXXXXXX/23 16XXXXXXXXion
10/23/23 1615
traMAXXXXXXXXfied
OrXXXXXXRY 6
10/23/23 1616
(ULTRAMXXXXblet
HOURS PRN
50 mg (PXXXXMaXXXXXXXX -
Moderate Pain
(tramadol))

PDF Page 30
Start
Stop StatXXXXXXXX
FrequXXXXXXXXXXXXX10/23/23 1615 HYDROmorphoXXXXXXXXied
IVPUSH
EXXXXXXXX0/23/23 1616
(PF) (DILAUDID)
HOUXXXXRN
injection 0.5-1
mgXXXXin
XXXXXXXXXXXXXSeverXXXXXXXX
HYDROXXXXXXXXXXXXXXX/23/23 1615
diphenhydrAMIXXXXXXXXied
IVPXXXXXXXXY 6
10/23/23 1616
(BENADRYL)XXXXXXXXRN
injXXXXXXXXXXXg
10/23/23 1615
simethiconXXXXXXXXified
OXXXXXXXIMES
10/23/23 1616
(MYLICON)
DAILYXXXXXXXXwable XXXXXXXXXXmg
10/23/23 1615
benzocaineXXXXXXXXified
Bucl
EVERY 4
10/23/23 1616
menthXXXXXXXXXXXN
(CHLORASEPTIC
SOREXXXXXXXX
6-10 XXXXXXXXXXXXXXXX23/23 1300
lactated ringers
-- VXXXXXXXXIV Drip
CONTINUXXXXXXXX3/23 1XXXXXXXXXXXXXXXX23/23 0800
lactated ringers
-- VXXXXXXXXIV Drip
CONTINUOUS 10/23/23 0740
infusion
Last 24 HRs of AdminsXXXXXXXXXXistrations since 10/24/2023 aXXXXXXXXXXelXXXXXXXXXXXXXd medication.
acetaminopXXXXXXXXXXXXXe
XXXXXXXDate
acetaminophen (TYLENOL) XXXXXXXXXX mg
650 mg
GivXXXXXXXXXX0XXXXXXXXXXGiven
10/24/2023
alprazoXXXXXXXXXXDoXXXXXtion
Date
ALPRAZolam (XANAX) spliXXXXXXXXXX5 mgXXXXXXXXXXXXXX0/XXXXXXXXXXXXyanocobalamin (vitamin B-XXXXXXXXXXXXXX
Action
Date
cyanocobalamin taXXXXXXXXXX mcg
1,000
Given
XXXXXXXXXX
mcg
XXXXXXXXXXn
10/24/2023
mcg
famotidXXXXXXXXXXDoXXXXXXion
Date
famotidine (PEPCIDXXXXXXXXXX0 mg
20 mg
GiXXXXXXXXXX2023
20 mg
Given
10/24/20XXXXXXXXXXgXXXXXXXXXXXXXXXXXXXXXX/2023
heparin sodium,porXXXXXXXdeXXXXXXXAction
Date
heparin (porcine) injectXXXXXXXXXXUnits
5,000
Given
1XXXXXXXXXXUnits
5XXXXXXXXXXX10/24/2023
Units
hydroxyXXXXXXXXXXXDoXXXXXXion
Date
hydroxyurea (HYDREA) XXXXXXXXXX0 mg
500 mg
GiXXXXXXXXXX2XXXXXXXXXXXGiven
10/24/2023
latanopXXXXXXXXXXXDoXXXXXXXon
Date
latanoprost (XALATAN) 0.005 % ophthalmic sXXXXXXXXXXdXXXXXXXXXXXXXXXXXX0/24/2023
ondansetron HCXXXXXXXXXXXDose
AcXXXXXXate
ondansetron (PF) (ZOFRANXXXXXXXXXXnXXXXXXXXXXXXXXXXXX0/25/2023
pravastatin soXXXXXXXXXXXDoXXXXXXXXX
Date
pravastatin (PRAVACHOXXXXXXXXXX2XXXXXXXXXX
XXXXXXXXXXXXXXX3
sennosides/docusate soXXXXXXXXXXXXXXe
XXXXXXXXXXe
senna-docusate (PERICOLACE) 8.6-50 mg per tabXXXXXXXXXXet
2 tablet
GXXXn
10/25/2023

PDF PagXXXXXXXXXXXXXXXX Last 72hrs
-Blood Smear Exam, RBC Morphology [LAB
Reflex Order#:
(Ord#:
Class: Lab Collect STANDING
Standing Order Information
Remaining Occurrences: 0/1 InterXXXXXXXXXXIXXXLaXXXreleased: 10/25/2023
CBC XXXXXXXXXXX#:
Spec. #
XXXXXXXXXX Collect
Resulted: 10/25/2023 6:19 AM AbnoXXXXXFXXXXXXXXXXt
Collected: Blood 10/25/2023 5:17 AM By:
Priority: Routine
Lab: CDH LAB
Component
ValuXXXlag
Low
High
Units
StaXuXXXBC
9.1
3.6
10.2
X0XXXuL
F
RBC
2.2X
XXX0^6/uL
F
HXBXXX5
L
g/dL
F
HCT
25.6
L
%
XXXCV
111.8
H
82.0
99.0
fLXXXXCH
37.1
H
27.0
33.0
pXXXXXXXC
33.2
32.0
36XXXg/dL
F
RDW
F
Not measurXdXXXT
128
L
150
450
10^XXXXXXXXXXXXXX
9.8
12X7XXXXXXXXXXXXXXXXXXCs
0.0
%
F
AbXoXXXe Nucleated
0.0
10XXXXXXXXXXXXXXXXXXXXXXXXXXs: Open
Basic Metabolic Panel [LAB
Order #:
Spec. #:
XXXXXXXXXX
Collect
Resulted: 10/25/2023 6:04 AM Abnormal FXXXXXXXXXXt
Collected: Blood 10/25/2023 5:17 AM
By:
Priority: Routine
Lab: CDH LAB
Component
ValuXXXXXX
Low
High
UnitXXXXXXXXXSodium
142
mXoXXXXXXXXtassium
3.9
mmXlXXXF
Chloride
10XXXXXXXXXL
F
CO2
27XmXXX/L
F
Anion GXXXXXXXXXXL
F
Bun
16
mg/dL
F
CreatXXXXXX0.XXXXXXX
1.30
mg/dL
F
eGFRcr (CKXXXXXXXXXXL/min/1.73 F
X0XXXXXXXCalcium
8.0
L
mg/dL
F
Glucose
109
H
mg/dL
F
XXXXXXXXXXXXXXXXXXXXXXStXXXXXXXXXXXXXXooXXXmear Exam, RBC Morphology [LAB]
Reflex Order#:
(Ord#:
Spec. #:XXXXXXXXXXb Collect
Resulted: 10/25/2023 6:19 AM AbnXXXXX XXXXXXXXXXlt
Collected: Blood 10/25/2023 5:17 AM
By:
Priority: Routine
Lab: CDH LAB
Component
ValXXXXXXXXXXXXXXgh
Units
StaXXXXXXXXXXXXXology
RevieXXXXXXXXlychromasiXXXXXXXXXXF
PLATELET
Normal
F
MORPHOLOGY - Hx
Upload
MacrocytosiXXXXXXXXXXXXXXXXXXXXXXStatus: Open
-Blood Smear Exam, RBC Morphology [LAB
Reflex Order#:
(Ord#:
Class: Lab Collect STANDING
Standing Order Information
Remaining Occurrences: 0/1
InteXXXXXXXXXXTXXX
Last released: 10/24/2XXXXXXXXwithout Differential (Hemogram) [LAB
Order #:
Spec. #:XXXXXXXXXXb Collect
Resulted: 10/24/2023 1:42 PM Abnormal XXXXXXXXXXlt
Collected: Blood 10/24/2023 12:57 PM
By:
Priority: Routine
Lab: CDH LAB
Component
ValXXXFlag
Low
High
Units
StatuX
XXX
10.8
H
3.6
10.2X1XXX/uL
F
RBC
2.X2XXX10^6/uL
F
XGXXX.0
L
g/dL
F
HCT
26.5
L
%XXXMCV
109.5
H
82.0
99.0
fXXXXMCH
37.2
H
27.0
33.0
pgXXXMXHC
34.0
32.0
3XXX
g/dL
F
RDW
F
Not measuXeXXXLT
125
L
150
450
10^XXXXXXXXXXXXXX0
9.8
12.XXXXXXXXXXXXXXXXXXBCs
0.0
%
F
Absolute Nucleated
0.0
1XXXXXXXXXXXXXXXXXXXXXXStXXXXXXXXXXXXXXood Smear Exam, RBC Morphology [LAB
Reflex OXXXXXXXXXXX#:
Spec. #:XXXXXXXXXXb Collect
Resulted: 10/24/2023 1:42 PM Abnormal Final resultXXXXXXXXXX 34
Collected: Blood 10/24/2023 12:57 PM By:
Priority: Routine
Lab: CDH LAB
Component
Value
Flag
Low
High
Units
Status
RBC Morphology
Reviewed
F
PLATELET
EnlXXXXXXXXXXXXHOLOGY - Hx
UpXoad
Macrocytosis
MXXXXXXXX!
A
F
Provider Status: XXXXXXXX without Differential (Hemogram) [LAB
Order #:
Class: Lab Collect
STANDING
Standing Order Information
Remaining Occurrences: 0/1 IntXXXXXXXXXX TIME
Last rXXXased: 10/24/2023
[CANCEXXXXXXXX wiXXXut Differential (Hemogram) [LAB
Order #:
Class:
Lab Collect STANDING
Standing Order Information
Remaining Occurrences: 1/1 InterXXXXXXXXXXXXXXXXXXXXXraw in AM
Basic Metabolic Panel [LAB
Order #:
Class: Lab Collect STANDING
Standing Order InfoXXXtion
Remaining Occurrences: 4/5 Interval: DAILYXXXXXXXXXXtime)
Last released: 10/25/20XXX[CANCELED] Type and Screen [LXXXXXXXXXXXXXXXssXXXab Collect
Magnesium LevelXXXAB
Order #:
Spec. #XXXXXXXXXXab
Collect
Resulted: 10/24/2023 5:34 AM XXXXXlXXXXXXXXXXult
Collected: Blood 10/24/2023 4:38 AM By:
Priority: Routine
Lab: CDH LAB
Component
VaXXXXXXXXXLow
High
Units
Status
Magnesium
1.9
1.7
2.8XXX/dXXX
Provider Status: Open
CBCXXXAB
Order #:
Spec. #XXXXXXXXXXab Collect
Resulted: 10/24/2023 5:19 AM AbXXXXXlXXXXXXXXXXult
Collected: Blood 10/24/2023 4:38 AM By:
Priority: Routine
Lab: CDH LAB
Component
VaXXX
Flag
Low
High
Units
SXaXXX
WBC
9.0
3.6
10.X
XXX3/uL
F
RBC
1.56XXX10^6/uL
F
HGB
6.4
LL
g/dL
F
HCT
19.7
L
%
F

PDF Page 35
Component
VXXXe
Flag
Low
High
Units
StXXXs
MCV
126.3
H
82.0
99.0XXXXF
MCH
41.0
H
27.0
33.0
XXXF
MCHC
32.5
32.0
3X.XXX/dL
F
RDW
12.8
11.0
15.X
XXX
PLT
117
L
150
45X
XXXXXXXXXXXXXX9.9
9.8
1XXXXXXXXXXXXXXXXXX RBCs
0.0
%
FXAXXXlute Nucleated
0.0
XXXXXXXXXXRBC
Result Narrative:
10/24/2023 5:18 AM: P indicates partial results on a panel have been released. XXXXXXXXXX results will
follow.
10/24/2023 5:19 AM: This result has been final verified. No additional or changed resultsXXXXXXXXXXXXXXXXXXXXXXXXXXatXXX Open
Basic Metabolic Panel [LAB
Order #:
Spec. XXXXXXXXXXLab
Collect
Resulted: 10/24/2023 5:34 AM AXXXXXaXXXXXXXXXXsult
Collected: Blood 10/24/2023 4:38 AM By:
Priority: Routine
Lab: CDH LAB
Component
VXXXXXXlag
Low
High
UXXXXXXXXXus
Sodium
138
XXXXXXXX
Potassium
4.6XmXXX/L
F
ChlorideXXXXXXXXXol/L
F
CO2X2XXXmol/L
F
AnioXXXXXXXXXXol/L
F
Bun
16
mg/dL
F
CrXXXXXXneXXXXXXX.60
1.30
mg/dL
F
eGFRcr XXXXXXXXXX6
mL/min/1.X3XXXXXXX)
m²
Calcium
8.7
mg/dL
F
Glucose
117
H
mg/dL
F
PXXXXXXXXXXatXXX Open
[CANCELED] Creatinine [LAB
Order #XXXXXXXXXXXXXXXllXXX
[CANCELED] PotasXXXm Level [LAB
Order #XXXXXXXXXXabXXXllect
[CANCELED] Creatinine [XXXXXXXXXXXXXXXasXXXLab Collect
Magnesium Level [LAB
Order #:
Class: Lab Collect STANDING
Standing Order Information
Remaining Occurrences: 0/1
Interval: Routine 1XXXXXXXXXX in AM
Last XXXXXXXXXX10XXX/2023
[CANCELED] Creatinine [LAB
Order #:
Class: Lab Collect STANDING
Standing Order Information
Remaining OccurrenceXXXX/1 Interval: Routine 1XXXXXXXXXX in AM
Last released: 10XXXXXXXXXXXXXXXagXXX6
[CANCELED] Potassium Level [LAB
Order #:
Class: Lab Collect STANDING
Standing Order Information
Remaining OccurrencXXXX0/1 Interval: Routine XXXXXXXXXXw in AM
LastXXXXXXXXXX 10/24/2023
[CANCELED] Creatinine [LAB
Order #:
Class: Lab Collect STANDING
Standing Order Information
Remaining Occurrences: 0/1 Interval: Routine XXXXXXXXXXwXXX AXXXast released: 10/24/2023
CBC [LAB
Order #:
Class: Lab Collect STANDING
Standing Order InXXXmation
Remaining Occurrences: 3/5 Interval: DAIXXXXXXXXXXyXXXXXXXXXXXXXXXXXXXXX 10/25/2023
BasXXXXXXXXXXXXXXXnel [LAB
Order #: 1766692107Class: Lab Collect STANDING
Standing Order Information
Remaining Occurrences: 0/1
Interval: Routine XXXXXXXXXXwXXXXXXXXXst releasXXXXXXXX4/2023
Blood Gas, Istat, Arterial [LAB
Order #:
Class: Unit Collect STANDING
Standing Order Information
RemaXXXXXXXXXurrences: 0/1 IntervaXXXXXXXXXXRXXXXXXXXXst releXXXXXXXX/23/2023
Blood Gas,Istat,Arterial [LAB
Order #:
Spec.XXXXXXXXXX
Lab Collect
Resulted: 10/23/2023 10:52 AM XXXXXmXXXXXXXXXXesult
Collected: Blood 10/23/2023 10:37 AM By:
Priority: Routine
Lab: CDH LAB
Component
ValuXXXXXXXXXXXXXXh
Units
XXXXusXXXXXXXXerial Blood
7.34
F
pCOX,XXXteXXXXXXXX7
35.0
45.0
mm Hg
F
po2, ArXeXXXX
2XXXXXXXX80.0
105.0
mm Hg
F
XCXXX ArteriaX
XXXL
22
26
mmol/LXXXXXX
2XXXXX
F
HGB
8.8
L
g/dL
F
SXXXXXXXXXXXXXXXXXXXXXXXXXXXq/L
F
Blood Gas
PotXssium Bld Gas
3.8
3.5
4.9
mEq/L
F
Ionized XXXXXXXXXXXXXXXXX2XXXXXXXXXXXX
F
Whole Blood
CTCO2 ArteXial POCXXXXXXXXXXXX
27.0
mmol/L
F
CSO2, Arterial POC 100
H
95
98
%
F
Provider Status: Open
SURGICAL PATHOLOGY [LAB
Order #:
Class: Clinic Performed STANDING
Standing Order Information
Remaining Occurrences: 0/1 Interval: RELEASE UPON ORDXXXXXXXXXX Page 37
Last released: 10/23/2023
